Light blue dots forming a diamond-shaped outline.

pipeline

ADVANCING A PIPELINE BUILT ON PRECISION

We’re advancing a pipeline built on precision, where each program teaches the next, and every success compounds value.

the pathos development model:
A Smarter System for Clinical Progress

Traditional pipelines progress in phases. Ours accelerates through engines that learn.

Each trial within the PathOS™ platform integrates multimodal data and adaptive AI to refine patient selection, optimize design, and accelerate clinical outcomes.

data-informed

AI-Enabled

AI-Enabled

Clinically Proven

Gradient of light green to white with a thin white bar in the middle.

programs in development

preclinical

phase 1

phase 2

phase 3

Pocenbrodib (CBP/P300 inhibitor)

preclinical

phase 1

phase 2

phase 3

preclinical

A vertical black line on a white background.
A single vertical black line against a white background.
A single, vertical black line on a white background.

Phase 1

Phase 2

Phase 3

Light blue circle.
Light blue circle.
Light blue circle.
Light blue circle.
Light blue circle.
Light blue circle on a white background.
Light blue circle.
Light blue circle.
A light-blue, circular shape with blurred edges against a lighter blue background.
White circle inside a gray ring.
White circle within a thin, dark outline.
White circle within a gray outline.
Circle outline, white interior. Black outline.
A white circle inside a dark gray circle.
White circle within a thin, dark gray outline.
Circle with gray outline, white center.
White circle within a gray outline.
White circle outlined in black.
White circle with a black outline against a blurred, colorful background.
White circle within a thin, dark gray outline.

Indication: Prostate, Breast, Multiple Myeloma

Additional Information

P-500 (PRMT5i)

preclinical

phase 1

phase 2

phase 3

preclinical

phase 1

phase 2

Vertical black line on white background.
A vertical black line on a white background.
A single, vertical black line on a white background.

Phase 3

Light blue circle.
Light blue circle.
Light blue circle, softly blurred.
Light blue circle.
Light blue circle.
Light blue, circular shape.
Light blue circle.
Light blue circle on a white background.
Light blue circle.
Light blue circle.
Light blue circle.
Light blue circle on white background.
Light blue circle.
White circle inside a gray ring.
White circle with black outline.
White circle with a black outline against a blurred, patterned background.
Circle with a gray outline and white center.
White circle inside a dark gray ring.
White circle with a thin black outline on a patterned background.
White circle with black outline.

Indication: Solid Tumors

Additional Information

*Pathos integrates patient selection data, mechanistic modeling, and trial intelligence into each program — creating a self-improving system that drives both scientific and commercial success.

Blank white background.

The Science Behind Data-Driven Discovery

Our translational research connects molecular mechanisms to real-world outcomes. Pathos collaborates with leading oncology institutions to publish, validate, and refine its platform across tumor types and therapeutic classes.

Abstract 6249: Probabilistic causal network models from real-world prostate cancer data identify potential synergistic combinations with CBP/P300 inhibitors.

scientific publication

Empty white space.

Leveraging probabilistic causal disease models to understand molecular pathways and target resistance mechanisms in Multiple Myeloma with the CREBBP and EP300 bromodomain inhibitor, pocenbrodib.

scientific publication

Empty white space.

Targeting resistance mechanisms to AR-targeted therapy in prostate cancer through inhibition of CREBBP/EP300.

scientific publication

Empty white background.

FT-6876, A Potent and Selective Inhibitor of CBP/p300 with Antitumor Activity in AR-Positive Breast Cancer.

scientific publication

A blank, white square.

The Courage Study: A First-In-Human Phase 1 Study of the CBP/p300 Inhibitor FT-7051 in Men With Metastatic Castration-Resistant Prostate Cancer.

scientific publication

Empty white space.

Leveraging probabilistic causal disease models to understand molecular pathways and target resistance mechanisms in Multiple Myeloma with the CREBBP and EP300 bromodomain inhibitor, pocenbrodib.

presentation

Empty white space.

Initial Findings From an Ongoing First-In-Human Phase 1 Study of the CBP/p300 Inhibitor FT-7051 in Men With Metastatic Castration-Resistant Prostate Cancer.

presentation

Empty white background.

A Phase 1 Study of the Protein Arginine Methyltransferase 5 (PRMT5) Brain-Penetrant Inhibitor PRT811 in Patients with Recurrent High-Grade Glioma or Uveal Melanoma.

presentation

White background.

Discovery of PRT811, a potent, selective, and orally bioavailable brain penetrant PRMT5 inhibitor for the treatment of brain tumors.

poster

A blank, white square.

A phase 1 dose-escalation study of protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor PRT811 in patients with advanced solid tumors, including recurrent high-grade gliomas.

poster

No image content.

FT‑6876, A Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor‑Positive Breast Cancer.

poster

Empty white background.

Learn more about the Pathos Platform

Each program teaches the next, advancing a repeatable model for precision drug development that compounds over time.

Right arrow, black, pointing towards the right.